Psoriasis Biologics Face Off in Drug Survival Study 

• by Julie Greenbaum

• January 14, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

• by Kathryn Wighton

• June 30, 2026

• 3 min

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.

• by Andrea Surnit

• July 9, 2026

• 3 min

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b

• by Mark Lebwohl, Andrew Blauvelt, Cynthia E. Kartman, Cianna Leatherwood, Kenneth B. Gordon, Naveed Sattar, Luis Puig, Joseph F. Merola, Kimberly Siu, Rona Wang, Luna Sun, Ann Leung, Najwa Somani, Maria Jose Rueda, Anabela Cardoso, Mark C. Genovese, April W. Armstrong, Bruce Strober

• July 1, 2026